Skip to search formSkip to main contentSkip to account menu

gantenerumab

Known as: Immunoglobulin G1, anti-(human 1-40-beta-amyloid/human 1-42-beta-amyloid) (human monoclonal gamma-1-chain), disulfide with human monoclonal kappa-chain, dimer 
A monoclonal antibody against beta-amyloid (Abeta40/42) used in the treatment of Alzheimer's disease. Gantenerumab targets and binds to beta amyloid… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Is Now the Time for Combination Therapies for Alzheimer Disease?
In this issue, Gauthier and colleagues from the European Union-North America Clinical Trials in Alzheimer Disease Task Force (EU… 
2018
2018
Higher Dose Gantenerumab leads to Significant Reduction in Amyloid Plaque Burden -Results for the Marguerite and Scarlet Road Open Label Extension Studies (S2.005)
Objective: To evaluate the efficacy of gantenerumab on amyloid burden assessed longitudinally with florbetapir PET. Background… 
2018
2018
Optimizing the Gantenerumab Phase 3 Dosing Regimen Through PK/PD Modeling and Clinical Trial Simulations (P6.179)
Objective: To combine available internal and external information and generate additional clinical safety data to confirm prior… 
2017
2017
Immunotherapy for the Treatment of Alzheimer’s Disease
Review
2016
Review
2016
Title : Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer ’ s disease patients
iRGD (internalizing RGD) with high affinity to αν integrins was reported to enhance tumor penetrability by binding to neuropilin… 
2016
2016
Résultats d’efficacité, de tolérance et des biomarqueurs de SCarlet RoAD—une étude de phase 3 internationale du gantenerumab chez des patients atteints d’une maladie d’Alzheimer (MA) à la phase…
Review
2015
Review
2015
Alzheimer's disease and other dementias: advances in 2014
2011
2011
Alzheimer Disease: Amyloid-targeting antibody performs well in phase II trial
The fully human monoclonal antibody gantenerumab, which targets amyloid-β plaques, seems to cause a dose-dependent decrease in… 
2011
2011
シンポジウム32―3 神経疾患に対する抗体療法 アルツハイマー病に対する抗体療法
In order to avoid Abeta-induced autoimmune encephalitis, several monoclonal and polyclonal antibodies are in clinical trials… 
1980
1980
News in brief
The UK Health Protection Agency (HPA) has warned about the need to develop new antibiotics before our current treatment options… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)